OptimizeRx Set to Join Russell Microcap® and 3000® Indexes
June 25 2019 - 8:31AM
OptimizeRx Corp. (Nasdaq: OPRX), a leading
platform for digital health messaging in the pharmaceutical
industry, is expected to join the Russell Microcap® and 3000®
Indexes at the conclusion of the 2019 Russell indexes annual
reconstitution, effective after the U.S. market opens on July 1,
according to a preliminary list of additions posted June 21.
Membership in the Russell Microcap and 3000 Indexes, which
remains in place for one year, means automatic inclusion in the
appropriate growth and value style indexes. FTSE Russell determines
membership for its Russell indexes primarily by objective,
market-capitalization rankings and style attributes.
“We are honored to be included in the Russell Indexes,” said
OptimizeRx CEO, William Febbo. “This marks a significant milestone
in the growth and trajectory of our company, reflecting our record
Q1 results, growing commercial team, and acquisition of CareSpeak.
We expect our inclusion in these indexes to raise awareness of
OptimizeRx across the investment community.”
Russell indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for
active investment strategies. Approximately $9 trillion in assets
are benchmarked against Russell’s US indexes. Russell indexes are
part of FTSE Russell, a leading global index provider.
For more information on the Russell indexes reconstitution, see
the “Russell Reconstitution” section on the FTSE Russell
website.
About OptimizeRxOptimizeRx® (Nasdaq: OPRX), a
digital health company, connects pharmaceutical companies to
patients and providers, offering greater affordability, adherence
and brand awareness at the point-of-care. As the nation’s largest
point-of-prescribe promotional platform for the pharmaceutical
industry, OptimizeRx provides a direct channel
for pharma companies to communicate with healthcare
providers right within their workflow.
The cloud-based solution supports patient adherence to
medications with real-time access to financial assistance, prior
authorization, education and critical clinical
information. OptimizeRx provides more than half of the
ambulatory patient market with access to these benefits through
leading EHR platforms like Allscripts, Amazing Charts and
Quest, and directly via its mobile communications
platform.
For more information, follow the company on Twitter, LinkedIn or
visit www.optimizerx.com.
About FTSE RussellFTSE Russell is a global
index leader that provides innovative benchmarking, analytics and
data solutions for investors worldwide. FTSE Russell calculates
thousands of indexes that measure and benchmark markets and asset
classes in more than 70 countries, covering 98% of the investable
market globally.
FTSE Russell index expertise and products are used extensively
by institutional and retail investors globally. Approximately $16
trillion is currently benchmarked to FTSE Russell indexes. For over
30 years, leading asset owners, asset managers, ETF providers and
investment banks have chosen FTSE Russell indexes to benchmark
their investment performance and create ETFs, structured products
and index-based derivatives.
A core set of universal principles guides FTSE Russell index
design and management: a transparent rules-based methodology
informed by independent committees of leading market participants.
FTSE Russell is focused on applying the highest industry standards
in index design and governance and embraces the IOSCO Principles.
FTSE Russell is also focused on index innovation and customer
partnerships as it seeks to enhance the breadth, depth and reach of
its offering.
FTSE Russell is wholly owned by London Stock Exchange Group.
For more information, visit www.ftserussell.com
Important Cautions Regarding Forward Looking
Statements
This press release contains forward-looking statements within
the definition of Section 27A of the Securities Act of 1933, as
amended, and such as in section 21E of the Securities Act of 1934,
as amended. These forward-looking statements should not be used to
make an investment decision. The words 'estimate,' 'possible' and
'seeking' and similar expressions identify forward-looking
statements, which speak only as to the date the statement was made.
The company undertakes no obligation to publicly update or revise
any forward-looking statements, whether because of new information,
future events, or otherwise. Forward-looking statements are
inherently subject to risks and uncertainties, some of which cannot
be predicted, or quantified. Future events and actual results could
differ materially from those set forth in, contemplated by, or
underlying the forward-looking statements. The risks and
uncertainties to which forward-looking statements are subject
include, but are not limited to, the effect of government
regulation, competition and other material risks.
OptimizeRx Contact Doug
Baker, CFO Tel (248) 651-6568
x807 dbaker@optimizerx.com
Media Relations Contact Nicole
Brooks, Innsena Communications Tel (860) 800-2344 nicolebrooks@innsena.com
Investor Relations Contact Ron Both,
CMA Tel (949) 432-7557 oprx@cma.team
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
From Apr 2023 to Apr 2024